comprehensive -WSS

comprehensive

author：entertainment 2025-09-27 13:10:13 - browse：6761

Gilead office remdesivir — Yichuan Cao/Sipa USA

Gilead Sciences said Monday it will acquire CymaBay Therapeutics for $4.3 billion, adding a new treatment for a liver disease that is on track for approval later this year.

The deal values CymaBay at $32.50 per share, 27% higher than the stock’s close last Friday. That’s a relatively small takeout premium, but CymaBay shares have doubled in value since last fall on growing investor confidence in the company’s lead drug and speculation that the company could be acquired.

CymaBay’s drug, called seladelpar, is being developed for the treatment of primary biliary cholangitis, or PBC, a type of liver disease mainly affecting women that causes decreased liver function, and debilitating itching and fatigue. Progression of PBC to more advanced stages increases the risk of liver-related death.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： After affirmative action ruling, medical educators look to 'holistic review'
Next article： 3 questions for the future of Biden's cancer moonshot

Wikipedia

WSS

Colorectal cancer study finds potential in overlooked immune cell

In shift, Texas to cover initial consult for Afghan baby's gene therapy

Hospital chaplains balance Covid safety with patients’ spiritual needs

JPM pitch from hospitals? Revenue streams outside of patient care

Analysis of telehealth claims data suggest service duplication

Life science postdocs should get big pay hike, NIH panel says

knowledge

comprehensive

entertainment

Duchenne breakthrough therapy leaves behind pioneering families

Profiling embryos to choose those with higher IQs is almost a reality

How one medical school became remarkably diverse

FDA panel signals lack of confidence in Amgen cancer drug data

ChatGPT in medicine: STAT answers readers' burning questions

FDA early review: GLP

Novavax promises a turnaround & Lilly roils the obesity market

In shift, Texas to cover initial consult for Afghan baby's gene therapy

Moonlake's readout produced a cash windfall. Risks remain

At JPM 2024, hospital systems pitch financial strength to investors

focus

The future of health care in the House

Stroke deaths set to near 10 million globally by 2050

Readout Newsletter: Biotech news, including Moderna's Covid vaccine

Liquid biopsy for lung cancer is launched by Delfi

Was Amgen transparent enough on FDA's concern on cancer drug?

Stroke deaths set to near 10 million globally by 2050

knowledge

Wikipedia

knowledge

explore